drugset / Trial / NCT04498117
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Phase 3
Active not recruiting
615 enrolled
CanariaBio Inc.
Gynecologic Oncology Group · collabIQVIA Pty Ltd · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.
Timeline
- Start
- 2020-08-25
- Primary completion
- 2026-12-26
- Completion
- 2028-08-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oregovomab | Monoclonal antibody | 2 mg | — |
| Background | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Background | Carboplatin | Small molecule | 6 unknown | Intravenous |
| Background | Paclitaxel | Small molecule | 175 mg/m2 | — |